Title: Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Journal: Expert review of anticancer therapy20080501
Title: Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
Journal: Biological & pharmaceutical bulletin20071201
Title: Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Journal: Pediatric blood & cancer20070801
Title: Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Journal: European journal of cancer (Oxford, England : 1990)20070401
Title: Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
Journal: Journal of pharmaceutical and biomedical analysis20070312
Title: Exatecan and gemcitabine: no better than gemcitabine only.
Journal: The Lancet. Oncology20061101
Title: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20060920
Title: Chemotherapy for advanced pancreatic cancer.
Journal: Best practice & research. Clinical gastroenterology20060401
Title: A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
Journal: Investigational new drugs20051001
Title: DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Journal: Investigational new drugs20050801
Title: A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
Journal: American journal of clinical oncology20050801
Title: Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Journal: Seminars in oncology20050801
Title: Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20050425
Title: A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
Journal: Cancer chemotherapy and pharmacology20050401
Title: Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Journal: Biomedical chromatography : BMC20050101
Title: Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
Journal: Thrombosis and haemostasis20041201
Title: A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Journal: Gynecologic oncology20041001
Title: A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20041001
Title: Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
Journal: Die Pharmazie20040501
Title: DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models.
Journal: Cancer science20040201
Title: A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Journal: Cancer chemotherapy and pharmacology20040101
Title: A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Journal: Investigational new drugs20040101
Title: Are there any better camptothecins than the ones we have?
Journal: Clinical advances in hematology & oncology : H&O20031001
Title: A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Journal: Cancer20030901
Title: Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)20030801
Title: A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20030701
Title: Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20030601
Title: [A symphony for the camptothecins].
Journal: Bulletin du cancer20030301
Title: Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Journal: Cancer research20030101
Title: The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
Journal: Biochemical pharmacology20021015
Title: Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Journal: British journal of cancer20020909
Title: Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20020701
Title: [Drug delivery systems for cancer chemotherapy].
Journal: Nihon Geka Gakkai zasshi20020201
Title: O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Journal: Japanese journal of cancer research : Gann20020101
Title: Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20011201
Title: Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Journal: Biomedical chromatography : BMC20010401
Title: Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20010301
Title: High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.
Journal: Biological & pharmaceutical bulletin20010201
Title: Morphological classification of dental lesions induced by various antitumor drugs in mice.
Journal: Toxicologic pathology20010101
Title: Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.
Title: Sun FX, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63(1):80-5.
Title: Joto N, et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer. 1997 Aug 7;72(4):680-6.
